|1.||Stasch, Johannes-Peter: 24 articles (11/2015 - 02/2003)|
|2.||Brouckaert, Peter: 14 articles (06/2015 - 08/2006)|
|3.||Felipo, Vicente: 11 articles (03/2010 - 02/2002)|
|4.||Bloch, Kenneth D: 10 articles (01/2015 - 06/2004)|
|5.||Buys, Emmanuel S: 10 articles (01/2015 - 01/2009)|
|6.||Grimminger, Friedrich: 8 articles (06/2015 - 01/2006)|
|7.||Frey, Reiner: 7 articles (06/2015 - 12/2008)|
|8.||Wolin, Michael S: 7 articles (08/2014 - 08/2003)|
|9.||Olshevskaya, Elena V: 7 articles (04/2014 - 08/2007)|
|10.||Dizhoor, Alexander M: 7 articles (04/2014 - 08/2007)|
|1.||Pulmonary Hypertension (Ayerza Syndrome)
11/01/2011 - "Although inhaled NO (iNO) therapy is often effective in treating infants with persistent pulmonary hypertension of the newborn (PPHN), up to 40% of patients fail to respond, which may be partly due to abnormal expression and function of soluble guanylate cyclase (sGC). "
09/01/2003 - "[Study on soluble guanylate cyclase in pulmonary hypertension rat model]."
04/08/2014 - "Soluble guanylate cyclase (sGC) plays a central role in the cardiovascular system and is a drug target for the treatment of pulmonary hypertension. "
01/01/2013 - "Soluble guanylate cyclase stimulators in pulmonary hypertension."
04/01/2011 - "Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension."
10/01/2009 - "The aim of this study was to explore the interaction between HIF-1alpha and soluble guanylate cyclase (sGC) and its second messenger cGMP in cultured cardiomyocytes exposed to hypoxia and in pressure-overloaded heart. "
07/01/2009 - "The present study explores the general hypothesis that chronic hypoxia also modulates cerebrovascular reactivity to NO, and does so by modulating the activity of soluble guanylate cyclase (sGC), the primary target for NO in vascular smooth muscle. "
10/01/1999 - "In this study, we examined the expression and localization of soluble guanylate cyclase (sGC), the primary receptor for NO, in hypoxia- and normoxia-treated rat lungs. "
12/01/2014 - "Depletion of SMC EC-SOD did not impact content or activity of lung soluble guanylate cyclase or PDE5, yet it blunted the hypoxia-induced increase in cGMP. "
01/01/2014 - "Soluble guanylate cyclase redox state under hypoxia or hypoxia/reoxygenation in isolated monkey coronary arteries."
03/01/2011 - "Also considered is the potential for therapeutic manipulation of intestinal guanylate cyclase/cGMP signaling for the correction of chronic constipation and gastrointestinal cancer. "
12/01/2011 - "Linaclotide is a guanylate cyclase-C agonist currently being studied in Phase 3 trials for the treatment of IBS with constipation. "
08/01/2014 - "Linaclotide is a first-in-class guanylate cyclase-C agonist approved for the treatment of adults with IBS-C and chronic idiopathic constipation in the United States. "
03/01/2011 - "Ongoing clinical trials have found that guanylate cyclase activating peptides are safe and effective in the treatment of constipation-predominant irritable bowel syndrome and chronic constipation. "
12/01/2010 - "Linaclotide, a minimally absorbed, 14-amino acid peptide agonist of guanylate cyclase-C, has shown benefit in a proof-of-concept study for the treatment of patients with irritable bowel syndrome (IBS) with constipation (IBS-C). "
|4.||Hypotension (Low Blood Pressure)
01/01/2014 - "In conclusion, these data suggest that the Oxime S1 induces hypotension and vasorelaxation via NO pathway by activating soluble guanylate cyclase (sGC) and K+ channels."
07/01/2007 - "The effect of inhibitors of soluble guanylate cyclase on anaphylactic hypotension were studied with either methylene blue (3.0 mg/kg) or 1H-[1,2,4]oxadiazole[4,3-a]quinoxalin-1-one (10 mg/kg). "
04/01/2002 - "The primary function of LAO is probably to promote prey hypotension by activating soluble guanylate cyclase in the presence of superoxide dismutase. "
01/01/1998 - "These peptide hormones act on many target organs via guanylate cyclase-linked membrane receptors to produce natriuresis, diuresis, vasodilatation, and hypotension. "
04/01/1994 - "The proposed mechanism by which NO produces hypotension is the activation of guanylate cyclase with subsequent biosynthesis of 3':5' cyclic guanosine monophosphate (cGMP). "
05/01/2012 - "In the last 2 decades, studies have reported promising results from the administration of an NO competitor, methylene blue (MB), which is an inhibitor of the soluble guanylate cyclase (sGC), in the treatment of refractory cases of vasoplegia. "
07/01/2009 - "There is strong evidence that methylene blue (MB), an inhibitor of guanylate cyclase, is an excellent therapeutic option for vasoplegic syndrome (VS) treatment in heart surgery. "
06/01/2003 - "Guanylate cyclase inhibitors could be a novel class of agents for the treatment of norepinephrine-refractory vasoplegia after cardiopulmonary bypass. "
05/01/2012 - "Guanylate cyclase inhibition by methylene blue as an option in the treatment of vasoplegia after a severe burn. "
01/01/2008 - "Thus, some points, to a certain extent philosophical, have motivated this revision: a) To preserve and update the surgeon knowledge regarding CPB, even to keep his/her pedagogical leadership on his/her surgical team; b) To question if elderly and diabetic patients, as a result of their individual characteristics deserve more appropriate protocols similar to those adopted for children; c) One third aspect would be the questioning of the systemic inflammatory reaction caused by the blood exposure to CPB non-endothelized circuit surface, in face of the increasing importance of blood contact with the surgical wound; d) In relation to the treatment of the vasoplegic syndrome, methylene blue continues being the best therapeutical option, even so, many times are not efficient on account of a highly probable existence of a "therapeutical window" based on the guanylate cyclase dynamics of action (saturation and synthesis "de novo") and; finally, e) The reason of the title, highlighting that based on its current patterns, would the CPB be an outcome of empiricism, art, or science? "
|1.||Methylene Blue (Methylthioninium Chloride)
|3.||Nitric Oxide Synthase (NO Synthase)
|4.||Nitric Oxide (Nitrogen Monoxide)
|6.||enterotoxin receptor (guanylyl cyclase C)
|7.||NG-Nitroarginine Methyl Ester (L-NAME)
|8.||5'-Guanylic Acid (GMP)
|9.||3- (4- Amino- 5- cyclopropylpyrimidine- 2- yl)- 1- (2- fluorobenzyl)- 1H- pyrazolo(3,4- b)pyridine
|2.||Cardiopulmonary Resuscitation (CPR)
|4.||Artificial Respiration (Mechanical Ventilation)
|5.||Drug Therapy (Chemotherapy)